侯雅楠证券分析师SAC No:S1150524120001行业要闻(1)国家组织高值医用耗材联采办发布《国家组织药物涂层球囊类、泌尿介入类医用耗材集中带量采购文件(GH-HD2025-1)》;(2)首个国产抗CTLA-4单抗信达生物达伯欣®(伊匹木单抗N01注射液)获国家药品监督管理局批准上市;(3)减重版司美格鲁肽在中国斩获心血管适应症。公司公告(1)丽珠集团:莱康奇塔单抗注射液上市许可申请获...
Source Link侯雅楠证券分析师SAC No:S1150524120001行业要闻(1)国家组织高值医用耗材联采办发布《国家组织药物涂层球囊类、泌尿介入类医用耗材集中带量采购文件(GH-HD2025-1)》;(2)首个国产抗CTLA-4单抗信达生物达伯欣®(伊匹木单抗N01注射液)获国家药品监督管理局批准上市;(3)减重版司美格鲁肽在中国斩获心血管适应症。公司公告(1)丽珠集团:莱康奇塔单抗注射液上市许可申请获...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.